Ivermectin, Mebendazole, Fenbendazole, Niclosamide and Atovaquone for Cancer: Evidence-Based Review (2026 Update)
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Originally Published: August 2025 | Last Updated: September 2026
Quick Answer
Ivermectin, mebendazole, atovaquone, fenbendazole and niclosamide are very different drugs that have attracted interest in oncology because laboratory studies suggest that they may affect cancer-relevant processes such as cellular metabolism, mitochondrial function, microtubules, tumor hypoxia, signaling pathways, drug resistance and immune activity.
The key point is that interesting biology is not the same thing as proven clinical benefit. The current evidence ranges from preclinical experiments to small early-phase studies and case reports. None has established efficacy for cancer through the kind of large, adequately controlled randomized trials normally required for a new cancer treatment.
Fenbendazole requires especially careful interpretation. Unlike ivermectin and mebendazole, it is not an established human antiparasitic medicine. It is used in veterinary medicine, its human pharmacokinetics and oncology safety profile are not well established, and several published case reports have described liver injury associated with self-administration. A 2025 case series claiming cancer remissions was subsequently retracted in January 2026.
The appropriate way to view these medicines is therefore as research hypotheses and potential repurposing candidates, not proven cancer treatments.
- Why are these drugs being studied in cancer?
- Ivermectin
- Mebendazole
- Atovaquone
- Fenbendazole
- Niclosamide
- Comparative mechanism and evidence table
- Evidence grading
- Safety and regulatory status
- Where these drugs fit in a cancer-resistance framework
- What the evidence does and does not show
- Frequently asked questions
- References
Why Are These Drugs Being Studied in Cancer?
Cancer is not a single disease. Different cancers — and even different tumors within the same cancer type — can have very different genetic, metabolic and immunologic characteristics.
This heterogeneity has driven interest in drug repurposing: investigating medicines that were developed for one indication to determine whether they might have another useful biological effect.
For oncology researchers, repurposed drugs can be attractive because their pharmacology, manufacturing and some aspects of safety may already be understood. However, the existence of previous human experience with a drug does not automatically establish that the drug is safe at an oncology dose or effective against cancer.
The five drugs in this article illustrate five different research strategies:
| Drug | Research rationale | Important distinction |
|---|---|---|
| Ivermectin | Cellular signaling, mitochondrial effects, autophagy and immune-related mechanisms | Human antiparasitic drug; cancer evidence remains investigational |
| Mebendazole | Microtubule disruption, angiogenesis and potential radiosensitization | Human antiparasitic drug with substantially more human-use experience than fenbendazole |
| Atovaquone | Mitochondrial complex III inhibition and reduction of tumor hypoxia | Established human medicine; oncology research has focused partly on radiosensitization |
| Fenbendazole | Microtubule effects, altered glucose metabolism and other preclinical mechanisms | Veterinary drug; human cancer evidence is extremely limited |
| Niclosamide | Wnt/β-catenin, STAT3, mitochondrial and other signaling effects | Human antiparasitic history but systemic oncology development is constrained by pharmacokinetics |
A major mistake is to treat the five drugs as if they were interchangeable. They are not.
1. Ivermectin
Ivermectin is a macrocyclic lactone antiparasitic drug with established human uses for selected parasitic infections. Interest in oncology comes primarily from laboratory studies suggesting effects on several cellular pathways.
Proposed anticancer mechanisms
Experimental studies have investigated ivermectin in relation to mitochondrial function, autophagy, cellular stress, P-glycoprotein and multidrug resistance, cancer stem-cell biology and immune-related signaling.
Some research has also proposed that ivermectin may alter the tumor microenvironment and influence immune-cell infiltration. However, these observations should be regarded as mechanistic or preclinical findings until replicated in well-controlled human trials.
A frequently cited preclinical study investigating "cold" versus "hot" tumor immunology has also undergone a publication correction in 2026. This is a useful reminder that highly cited laboratory findings still require independent verification before they become clinical conclusions.
Human research
Ivermectin has entered early-stage clinical investigation in cancer, including studies evaluating combinations with immune checkpoint inhibitors. These trials are important because they can determine whether the biological hypotheses translate into tolerable exposure and meaningful patient outcomes.
At present, however, there is no robust randomized evidence establishing ivermectin as an effective cancer treatment.
2. Mebendazole
Mebendazole is a benzimidazole anthelmintic used in humans for intestinal helminth infections. It has attracted oncology interest for more than a decade, particularly because laboratory studies indicate effects on microtubules, angiogenesis and tumor-cell survival.
Why is mebendazole interesting?
Microtubules are essential components of cell division. Interfering with microtubule dynamics is an established strategy in oncology because rapidly dividing cells can be particularly vulnerable to disruption of mitosis.
Preclinical studies have also investigated mebendazole in glioma and other cancers, including combinations with radiation and conventional therapies.
Human evidence
Compared with fenbendazole, mebendazole has a much larger history of human medical use. Nevertheless, human antiparasitic safety experience should not be confused with proof of anticancer efficacy.
Early clinical studies and case reports have produced hypotheses worth investigating, but larger controlled trials are required before mebendazole can be considered established cancer therapy.
3. Atovaquone
Atovaquone is an established human medicine used for malaria and Pneumocystis jirovecii pneumonia. Its oncology research profile is quite different from the benzimidazole drugs.
Targeting tumor hypoxia
One of the most interesting hypotheses is that atovaquone can inhibit mitochondrial complex III and reduce oxygen consumption.
Because hypoxic tumor regions can be relatively resistant to radiation and some systemic treatments, reducing tumor hypoxia could potentially improve the response to other therapies.
This has led to clinical investigation of atovaquone as a potential tumor-hypoxia modifier or radiosensitizing strategy, rather than simply as a conventional cytotoxic cancer drug.
Human studies
Early studies have evaluated atovaquone with chemoradiotherapy and used imaging biomarkers to assess changes in tumor hypoxia. These studies are scientifically useful because they test a measurable mechanism in humans.
They do not, however, demonstrate that atovaquone improves overall survival across cancer populations.
4. Fenbendazole
Fenbendazole is the most important new addition to this review — and the drug that requires the greatest evidence caution.
Fenbendazole is a benzimidazole anthelmintic used in veterinary medicine. It is not an FDA-approved human medicine. FDA materials identify approved fenbendazole products for veterinary use in animals including dogs, cats and horses.
Its growing popularity in cancer discussions largely comes from preclinical research, online patient communities and anecdotal reports rather than established clinical oncology evidence.
Why is fenbendazole scientifically interesting?
Laboratory studies have suggested several possible anticancer mechanisms.
One study reported that fenbendazole can act as a moderate microtubule-destabilizing compound and can affect cancer-cell metabolism. The researchers reported effects on glucose uptake, GLUT transporters and hexokinase II, as well as mitochondrial localization of p53 and tumor growth inhibition in a mouse xenograft model.
These observations are interesting because cancer cells frequently exhibit altered glucose metabolism and dependence on specific metabolic pathways. But laboratory activity does not establish that the same effects occur at safe and achievable concentrations in humans.
This distinction is particularly important for fenbendazole because its human pharmacokinetics and therapeutic exposure have not been adequately characterized.
Fenbendazole versus mebendazole
Fenbendazole and mebendazole are both benzimidazoles, but that does not make them interchangeable.
| Characteristic | Fenbendazole | Mebendazole |
|---|---|---|
| Drug class | Benzimidazole anthelmintic | Benzimidazole anthelmintic |
| Established human antiparasitic use | No | Yes |
| Veterinary use | Yes | Not its primary human role |
| Human oncology approval | No | No |
| Human oncology evidence | Very limited; primarily preclinical and case reports | Early clinical studies and case reports |
| Established oncology dose | No | No |
The fact that two compounds belong to the same chemical class does not mean they have identical absorption, metabolism, tissue distribution, pharmacologic potency or clinical safety.
What happened to the 2025 fenbendazole cancer case series?
In May 2025, a paper in Case Reports in Oncology described three patients with advanced cancer who had self-administered fenbendazole alongside other therapies and reported major tumor responses.
That paper should not be cited as current evidence of fenbendazole efficacy. In January 2026, the publisher and editor retracted the article because of concerns about an undeclared conflict of interest involving the first author. The retraction therefore materially changes the evidentiary status of those reported cases.
This is an important lesson for patients and health publishers: an apparently dramatic case series can generate a hypothesis, but the evidence must remain auditable and its publication status must be checked before drawing conclusions.
Fenbendazole and liver injury
Safety deserves particular attention.
A published 2021 case report described severe liver injury in an 80-year-old patient with advanced non-small-cell lung cancer who had self-administered fenbendazole after reading social-media reports. Liver dysfunction improved after the drug was stopped, and tumor shrinkage was not observed.
Additional 2025–2026 reports have described fenbendazole-associated liver injury, including cases involving patients receiving immunotherapy and a 2026 case involving concurrent veterinary fenbendazole and ivermectin use.
These reports do not establish the incidence of fenbendazole hepatotoxicity. They do establish something clinically important: fenbendazole cannot be assumed to be harmless simply because it is a veterinary antiparasitic drug.
What does ASCO say?
In June 2026, the American Society of Clinical Oncology issued a clinical notice addressing ivermectin and fenbendazole. ASCO stated that these agents should not be used to treat cancer, including as adjuncts to established cancer therapy, outside the regulatory safeguards of a well-designed clinical trial.
ASCO specifically highlighted two concerns: the absence of established clinical benefit and the possibility of toxicity and harmful drug interactions.
This does not mean the biological research should stop. It means the question has moved into territory where proper clinical trials are needed.
5. Niclosamide
Niclosamide is another repurposing candidate with a long history as an antiparasitic drug. Its cancer research has focused on several signaling pathways rather than a single mechanism.
Potential anticancer mechanisms
Preclinical research has investigated niclosamide in relation to:
- Wnt/β-catenin signaling
- STAT3 signaling
- NF-κB and Notch pathways in selected models
- mitochondrial oxidative phosphorylation
- macropinocytosis and nutrient transport
- androgen-receptor splice variants in prostate cancer
The bioavailability problem
Niclosamide illustrates an important principle in drug repurposing: a drug can have an attractive mechanism yet still fail to translate clinically because the required tissue exposure cannot be achieved safely with the original formulation.
Because conventional niclosamide has relatively poor systemic absorption, investigators have explored reformulated versions and delivery systems designed to improve exposure.
This means that a laboratory concentration that kills cancer cells cannot simply be translated into a recommendation to take a conventional antiparasitic preparation.
Comparative Mechanism, Human Evidence and Development Status
| Drug | Original medical use | Selected cancer-relevant mechanisms under study | Human oncology evidence | Current interpretation |
|---|---|---|---|---|
| Ivermectin | Human antiparasitic | Mitochondrial effects, autophagy, signaling, P-gp/MDR, immune-related mechanisms | Early-phase clinical research | Investigational |
| Mebendazole | Human antiparasitic | Microtubules, angiogenesis, radiosensitization | Early clinical studies and case reports | Investigational |
| Atovaquone | Human antimalarial / anti-Pneumocystis | Mitochondrial complex III inhibition, reduced tumor hypoxia | Early-phase human studies | Investigational for cancer |
| Fenbendazole | Veterinary antiparasitic | Microtubule effects, glucose uptake, GLUT/HKII, p53-related mechanisms | Very limited case reports; no robust efficacy trials | Highly investigational |
| Niclosamide | Antiparasitic | Wnt/β-catenin, STAT3, mitochondrial effects, AR splice variants | Early-phase human studies | Investigational |
Evidence Grading
For this review, we use a simplified CEBM-style framework to distinguish biological plausibility from meaningful clinical evidence.
| Level | General meaning | Examples in this article |
|---|---|---|
| Level 1 | Systematic review or meta-analysis of high-quality randomized evidence | None of these drugs currently qualifies for an established cancer indication |
| Level 2 | Individual randomized trial or strong prospective comparative evidence | None has established a cancer indication at this level |
| Level 3 | Non-randomized controlled evidence | Very limited for the drugs discussed here |
| Level 4 | Case series, uncontrolled trials or early clinical studies | Relevant to some ivermectin, mebendazole, atovaquone and niclosamide research |
| Level 5 | Mechanistic, preclinical or expert-opinion evidence | Fenbendazole is primarily in this category |
These grades are not statements that a drug "works" or "doesn't work." They describe how confidently we can infer clinical benefit from the available evidence.
Safety, Regulatory Status and Drug Interactions
One of the most persistent misconceptions surrounding repurposed drugs is that an old drug automatically means a safe cancer drug.
That is not how oncology pharmacology works.
A medicine can have an established safety record at one dose, for one indication, for a limited duration, while having a completely different risk profile when used at a different dose, in a different population, for months, or in combination with multiple cancer treatments.
| Drug | Human medical status | Major evidence limitation for cancer |
|---|---|---|
| Ivermectin | Approved human antiparasitic | No established anticancer efficacy; potential interactions and toxicity at inappropriate exposure |
| Mebendazole | Approved human antiparasitic | Oncology doses and long-term cancer-specific safety remain incompletely established |
| Atovaquone | Approved human medicine | Oncology benefit remains unproven |
| Fenbendazole | Veterinary drug; not approved for human use | Human pharmacokinetics, dosing, long-term safety and efficacy are inadequately established |
| Niclosamide | Established antiparasitic history | Poor systemic bioavailability creates a major translational challenge |
Fenbendazole deserves additional caution
Fenbendazole is fundamentally different from mebendazole because patients cannot rely on the same breadth of established human clinical experience.
Its veterinary status also creates practical concerns relating to formulation, product quality, dosing consistency and the absence of an established human therapeutic window.
The reported cases of liver injury are particularly relevant for people taking multiple drugs, including cancer therapies that can themselves affect liver function.
Any unexplained elevation in liver enzymes, bilirubin, jaundice, dark urine, abdominal pain or other symptoms during cancer treatment requires medical evaluation rather than an assumption that the problem is caused by the cancer or by conventional therapy.
Where Could Repurposed Drugs Fit in a Cancer-Resistance Framework?
Cancer treatment resistance is one reason these drugs continue to attract research interest.
Resistance is rarely caused by a single pathway. A tumor can simultaneously change signaling, metabolism, drug efflux, DNA repair, apoptosis, immune evasion and the tumor microenvironment.
That creates a potential rationale for investigating multiple mechanistically distinct agents rather than searching for a single "magic bullet."
But this concept must not be confused with evidence that stacking multiple repurposed drugs improves patient survival.
| Resistance problem | Research hypothesis | Drug examples studied | Clinical certainty |
|---|---|---|---|
| Altered cellular metabolism | Disrupt tumor energy production or glucose utilization | Fenbendazole, ivermectin, niclosamide, atovaquone | Primarily preclinical |
| Microtubule-dependent proliferation | Disrupt mitosis and cytoskeletal function | Mebendazole, fenbendazole | Preclinical to early clinical |
| Tumor hypoxia | Reduce oxygen consumption and improve radiation sensitivity | Atovaquone | Early clinical evidence |
| Aberrant signaling | Interfere with pathways such as Wnt/β-catenin or STAT3 | Niclosamide | Preclinical to early clinical |
| Immune evasion | Modify tumor-cell stress or the immune microenvironment | Ivermectin | Primarily preclinical / early clinical |
The important distinction is between a mechanistic map and a validated treatment strategy. A mechanism can explain why researchers are interested in a drug without proving that the drug improves progression-free survival or overall survival in humans.
What the Evidence Does — and Does Not — Show
Taken together, these five compounds demonstrate why drug repurposing is simultaneously promising and difficult.
On the promising side, each drug has a biological rationale that can be tested. Some have already moved into early human studies, and some have measurable pharmacodynamic effects that investigators can study in patients.
On the other hand, cancer is highly heterogeneous. A mechanism demonstrated in a pancreatic cancer cell line may not translate to a resistant colorectal cancer in a patient. A concentration effective in vitro may not be achievable in human tumor tissue without unacceptable toxicity. And even if a biological marker changes, that does not necessarily mean the patient lives longer.
Fenbendazole provides the clearest example of this evidence gap. It has generated substantial public interest because of laboratory findings and anecdotal cancer reports, but its human evidence remains extremely limited. The retraction of the widely circulated 2025 case series further reduces the reliability of that particular evidence source, while the 2026 ASCO notice and recent liver-injury reports reinforce the need for caution.
That does not mean fenbendazole research is scientifically irrelevant. It means the correct question is not "Why isn't everyone taking it?" but rather:
"Can carefully designed clinical research determine whether fenbendazole has a favorable benefit-to-risk profile in any specific human cancer setting?"
That is a legitimate research question. It is very different from claiming that fenbendazole is an effective cancer treatment.
Repurposed Drugs Are Not a Substitute for Standard Cancer Therapy
Patients with advanced cancer often investigate every plausible option, particularly when standard treatment options are limited or when a tumor becomes treatment-resistant.
That search for additional options is understandable. But evidence quality becomes even more important when the disease is aggressive.
These medicines should not be used to delay, replace or undermine treatments with established survival benefit. For people considering an investigational or off-label approach, the most useful framework is to discuss the idea with the treating oncology team and identify whether the hypothesis can be studied safely through a regulated clinical trial.
The goal should not be "alternative medicine versus conventional medicine." The more useful question is whether a particular intervention has sufficient biological rationale, clinical evidence, safety information and patient-specific relevance to justify further investigation.
Frequently Asked Questions
Is fenbendazole a proven cancer treatment?
No. Fenbendazole is not an approved human cancer treatment, and there is currently no robust clinical evidence demonstrating that it safely and effectively treats any human malignancy. ASCO specifically advises against using fenbendazole for cancer outside a well-designed clinical trial.
Is fenbendazole FDA approved?
Fenbendazole products are approved for veterinary use, not as a human cancer treatment. The FDA identifies fenbendazole products for animal use. It is not an FDA-approved human oncology medicine.
Is fenbendazole the same as mebendazole?
No. They are both benzimidazole compounds, but they are different drugs. Mebendazole has established human medical use for parasitic infections, whereas fenbendazole is primarily a veterinary medicine. They should not be considered interchangeable.
Can fenbendazole be taken with ivermectin?
There is no established cancer-treatment regimen demonstrating that the combination is safe or effective. A 2026 case report described severe drug-induced liver injury following concurrent veterinary fenbendazole and ivermectin use for prostate cancer. This is one reason self-directed combinations are particularly difficult to evaluate safely.
Did a 2025 study show that fenbendazole cured cancer?
No. A 2025 case series reported three patients with advanced cancer who had self-administered fenbendazole alongside other therapies. However, the paper was subsequently retracted by the publisher and editor in January 2026 because of concerns about an undeclared conflict of interest. It should not be used as reliable evidence that fenbendazole cures cancer.
Has fenbendazole caused liver injury in humans?
There are published case reports describing clinically significant liver injury associated with fenbendazole use, including reports involving patients receiving cancer immunotherapy and a 2026 report involving concurrent fenbendazole and ivermectin. These reports do not establish how common the problem is, but they demonstrate that serious toxicity is possible.
Is ivermectin proven to treat cancer?
No. Ivermectin has several interesting preclinical mechanisms and has entered early clinical research, but it has not established anticancer efficacy through large randomized trials.
Is mebendazole proven to treat cancer?
No. Mebendazole has a substantial history of human use as an antiparasitic medicine and has attracted significant preclinical and early clinical oncology research, but it remains investigational for cancer.
Why is atovaquone being studied in cancer?
Atovaquone inhibits mitochondrial complex III and can reduce cellular oxygen consumption. Researchers have therefore investigated whether it can reduce tumor hypoxia and potentially improve the effects of radiation or other treatments.
Why is niclosamide interesting in colorectal and prostate cancer?
Niclosamide has been studied for effects on pathways including Wnt/β-catenin and STAT3 and, in prostate cancer models, androgen-receptor splice variants associated with treatment resistance. However, systemic exposure and bioavailability remain important limitations.
Are these five drugs interchangeable?
No. Their mechanisms, pharmacokinetics, approved uses, human safety experience and clinical evidence are different. Treating them as one category of equivalent "anti-cancer drugs" oversimplifies the evidence.
What is the most important next step for this research?
Prospective, independently monitored clinical trials are needed. The key question is not whether a drug can kill cancer cells in a laboratory but whether it can produce a meaningful clinical benefit at an exposure that patients can tolerate safely.
Bottom Line
Ivermectin, mebendazole, atovaquone, fenbendazole and niclosamide remain scientifically interesting examples of drug repurposing in oncology, but they sit at different points on the evidence spectrum.
Fenbendazole should be regarded as the most preliminary of the five. Its laboratory mechanisms justify further investigation, but its veterinary status, limited human pharmacology, absence of convincing clinical efficacy data, reported liver injuries and the retraction of a high-profile 2025 case series make it inappropriate to present as an established cancer therapy.
The broader lesson is important: mechanism is not efficacy, anecdote is not a clinical trial, and a repurposed drug is not automatically a safe cancer drug.
For patients with cancer, especially advanced or treatment-resistant disease, these distinctions matter. Research into repurposed drugs should continue — but it should move from anecdote and internet claims toward transparent, adequately designed human trials.
References and Further Reading
- American Society of Clinical Oncology (ASCO). Oncologists Urged to Take Proactive Approach When Discussing Ivermectin, Fenbendazole . June 17, 2026.
- U.S. Food and Drug Administration. Bulk Drug Substances Reviewed and Not Listed — Fenbendazole .
- Son DS, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways . Scientific Reports. 2018.
- Oral Fenbendazole for Cancer Therapy in Humans and Animals . Anticancer Research. 2024.
- Matsumoto Y, et al. Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information . Case report. PMID: 34248555.
- Skaara TR, et al. Cholestasis following use of fenbendazole as alternative cancer treatment . 2025.
- Powderly GE, et al. Drug-Induced Liver Injury Following Co-ingestion of Veterinary Fenbendazole and Ivermectin for Prostate Cancer: A Case Report . Cureus. 2026.
- Satinsky A, et al. Fenbendazole-Associated Drug-Induced Liver Injury with Concomitant Use of Tauroursodeoxycholic Acid . ACG Case Reports Journal. 2026.
- Karger Publishers. Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients” . Case Reports in Oncology. 2026.
- Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients . Retracted. Case Reports in Oncology. 2025.
- ClinicalTrials.gov. Ivermectin cancer clinical-trial search .
- ClinicalTrials.gov. Mebendazole cancer clinical-trial search .
- ClinicalTrials.gov. Atovaquone cancer clinical-trial search .
- ClinicalTrials.gov. Niclosamide cancer clinical-trial search .
Editorial standard: OneDayMD distinguishes preclinical evidence, observational evidence, case reports and controlled clinical trials. A mechanistic finding or anecdotal response is not treated as proof of clinical efficacy. This page should be updated when new controlled human data, regulatory decisions, safety signals or publication corrections materially change the evidence.
.png)
.png)
Comments
Post a Comment